Inhibrx Biosciences, Inc. INBX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s total liabilities?
- Inhibrx Biosciences, Inc. (INBX) reported total liabilities of $205M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s total liabilities changed year-over-year?
- Inhibrx Biosciences, Inc.'s total liabilities increased by 38.3% year-over-year, from $148.2M to $205M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s total liabilities?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s total liabilities has grown at a -27.6% compound annual growth rate (CAGR), from $264.39M to $138.49M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.